Up­start sets off on a clin­i­cal jour­ney, look­ing to make a name for its 2nd-gen CB1 block­ers

A small Mon­tre­al-based biotech out to make a name for it­self as a sec­ond-gen de­vel­op­er of CB1 re­cep­tor block­ers has suc­cess­ful­ly gath­ered $35 mil­lion for the next stage of the de­vel­op­ment odyssey it’s on.

The mon­ey, which comes from a high-pro­file group of transat­lantic in­vestors, will be used to pay for the first clin­i­cal for­ays of In­ver­sa­go’s lead drug. And the biotech has a long list of high-pro­file tar­gets in mind, start­ing with Prad­er-Willi syn­drome and run­ning through NASH, type 1 di­a­betes and di­a­bet­ic nephropa­thy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER